Hyzaar

Losartan potassium and hydrochlorothiazide, the active ingredients in Hyzaar, are an angiotensin II receptor blocker and a thiazide diuretic presented as oral tablets for systemic use. They are prescribed to manage essential hypertension in adult patients.

GNH USA supplies Hyzaar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hyzaar is used to treat hypertension by targeting the renin‑angiotensin system and promoting diuresis. - Essential hypertension: lowers systolic and diastolic blood pressure and reduces cardiovascular risk. - Hypertension requiring diuretic therapy: adds fluid‑removing effect to improve blood‑pressure control. - Hypertension with fluid retention: helps reduce extracellular volume while blocking angiotensin‑II‑mediated vasoconstriction.

Hyzaar may cause a range of adverse reactions. Most are mild and reversible.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Hyperkalemia - Acute kidney injury - Angioedema or severe allergic reaction - Pancreatitis - Significant drop in blood pressure (hypotension).

Before initiating Hyzaar, consider the following safety measures. - Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Renal function assessment: check serum creatinine and eGFR regularly. - Electrolyte surveillance: monitor potassium and sodium levels, especially when combined with other diuretics. - Pregnancy and lactation: avoid use unless benefits outweigh risks, as safety data are limited. - Concomitant potassium supplements or potassium‑sparing agents: use with caution to prevent hyperkalemia. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Hyzaar can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal impairment. - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - ACE inhibitors or other ARBs: additive effect on potassium and renal function. - Lithium: may increase lithium serum concentrations. - NSAIDs: can blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives: may cause additive blood‑pressure lowering. - Antidiabetic agents: blood‑glucose control may improve, requiring dose adjustment. - Cyclosporine or tacrolimus: increased risk of nephrotoxicity. - Rifampin or other enzyme inducers: may reduce plasma levels of losartan. - Digoxin: altered renal clearance may affect digoxin levels.